	US 11,857,645 B2
	Compositions of near IR closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands
Jonathan M. Sorger, Belmont, CA (US)
Assigned to Intuitive Surgical Operations, Inc., Sunnyvale, CA (US)
Filed by Intuitive Surgical Operations, Inc., Sunnyvale, CA (US)
Filed on Dec. 4, 2020, as Appl. No. 17/112,075.
Application 17/112,075 is a continuation of application No. 16/593,207, filed on Oct. 4, 2019, granted, now 10,888,629.
Application 16/593,207 is a continuation of application No. 15/261,357, filed on Sep. 9, 2016, abandoned.
Claims priority of provisional application 62/324,097, filed on Apr. 18, 2016.
Prior Publication US 2021/0154332 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 8/00 (2006.01); A61B 10/00 (2006.01); A61K 49/00 (2006.01); A61K 9/00 (2006.01); G01N 33/574 (2006.01); C09B 23/01 (2006.01)

CPC A61K 49/0052 (2013.01) [A61K 9/0019 (2013.01); A61K 49/0032 (2013.01); A61K 49/0034 (2013.01); C09B 23/0025 (2013.01); C09B 23/0066 (2013.01); G01N 33/57434 (2013.01)]

20 Claims

1. A sterile, non-toxic pharmaceutical composition suitable for administration to a patient, comprising:

(a) a pharmaceutically acceptable excipient; and

(b) a unit dosage form of a compound having the formula:

wherein:

R¹, R², R³, R⁴, R⁵, R⁶, and R⁷are each independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;

X is selected from the group consisting of a single bond, —O—, and —S—;

subscripts a, b, c, d, e, f, g, and h are each independently an integer selected from 1 to 6;

each T is independently selected from the group consisting of a metal ion, H, and a negative charge; and

each Z is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, branched pentyl, n-hexyl, and branched hexyl, and

wherein the unit dosage form delivers to the patient between 0.01 and 8 mg/kg of the compound of formula (I); and

wherein the pharmaceutical composition is adapted for visualization of tissue expressing PSMA under illumination at wavelengths ranging from 700 to 1400 nm.